Sandhoff Disease vs. Tay-Sachs Disease: Key Differences

Both are GM2 gangliosidoses—lysosomal storage disorders causing neurodegeneration—but differ in enzyme defect, genetics, and epidemiology.

Comparison

Feature	Tay-Sachs Disease	Sandhoff Disease
Deficient enzyme	Hexosaminidase A (Hex A)	Hexosaminidase B (Hex B) → loss of both Hex A & Hex B activity
Gene	HEXA (chr15)	HEXB (chr5)
Stored substrate	GM2 ganglioside (neuronal lysosomes)	GM2 ganglioside + globoside (GA2) in lysosomes & cytoplasm
Ethnic predilection	Ashkenazi Jewish (1:30 carrier), French Canadian, Cajun, Irish American	Pan-ethnic; no founder population (higher in Creole, Metis, Lebanese)
Onset/forms	Infantile (classic), juvenile, adult (late-onset)	Infantile (classic), juvenile, adult
Infantile phenotype	Onset 3–6 mo: developmental arrest, cherry-red spot, startle, hypotonia → spasticity, blindness, seizures. Death by 4–5 yrs.	Similar + visceral involvement (hepatosplenomegaly, bone abnormalities) due to globoside storage.
Diagnosis	Hex A activity (serum/leukocytes) <10%; HEXA sequencing	Hex A & B deficiency; HEXB sequencing
Carrier screening	Standard in high-risk groups	Included in expanded panels

Management

• Supportive only: seizure control, nutrition (G-tube), respiratory care, spasticity management.
• No disease-modifying therapy yet. Gene therapy, substrate reduction, chaperones in trials.
• Genetic counseling essential for families.

Both are devastating. Carrier screening prevents births; research seeks treatment.